REGN
Regeneron Pharmaceuticals Inc
788.00$
-1.0%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 64.7% | 60.3% | 56.1% | 63.9% | 67.8% | 51.9% | 74.3% | 55.1% | 54.4% | 58.9% | 49.4% | 44.4% | |
| 16.8% | 14.4% | 7.7% | 9.3% | 12.5% | 10.9% | 12.8% | 11.3% | 10.6% | 8.3% | 6.6% | 7.7% | |
| 35.1% | 29.9% | 14.9% | 33.0% | 38.9% | 21.7% | 39.2% | 22.4% | 26.5% | 32.8% | 23.9% | 21.2% | |
| 26.3% | 26.2% | 23.1% | 22.5% | 19.1% | 18.8% | 24.0% | 23.7% | 18.2% | 17.1% | 16.5% | 14.2% | |
| 3.3% | 4.3% | 5.7% | 8.3% | 9.8% | 9.6% | 11.2% | 7.7% | 8.2% | 7.8% | 8.2% | 7.9% | |
| 25.2% | 28.4% | 29.9% | 26.9% | 22.0% | 19.5% | 18.8% | 13.7% | 12.9% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | -26.9% | – | 0.0% | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | 0.0% | 3.1% | 3.1% | 3.0% | 3.1% | |
| 34.3% | 34.8% | 36.2% | 29.9% | 25.4% | 25.1% | 35.8% | 26.2% | 22.4% | 21.5% | 22.3% | 22.9% | |
| 16.0% | 13.6% | 17.8% | 11.0% | 11.5% | 14.2% | 16.4% | 15.5% | 10.8% | 10.3% | 10.4% | 10.8% | |
| 9.0% | 8.1% | 1.9% | 5.3% | 0.8% | – | 9.5% | 2.8% | 2.5% | – | – | 0.1% | |
| 2.6% | 2.5% | 1.9% | 2.0% | 1.9% | 2.8% | 2.8% | 2.2% | 2.0% | 1.8% | 2.1% | 2.3% | |
| 3.8% | 6.5% | 5.0% | 8.0% | – | – | 11.5% | 7.8% | 6.8% | 6.0% | 5.3% | 4.9% | |
| 65.7% | 65.2% | 63.8% | 70.1% | 74.6% | 74.9% | 64.2% | 73.8% | 77.6% | 78.5% | 77.7% | 77.1% | |
| 6.6% | 15.2% | 25.1% | 33.6% | 44.8% | 49.8% | 63.5% | 74.6% | 79.8% | 82.4% | 83.9% | 88.3% | |
| 2.9% | 2.1% | 1.7% | 1.3% | 1.0% | 0.8% | 0.7% | 0.4% | 0.4% | 0.3% | 0.3% | 0.3% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.